EKO Devices https://ekodevices.com heavily involved in developing and using non-invasive, mobile, and intelligent cardiac care has been approved by FDA to market DUO a combined digital stethoscope and electrocardiogram (ECG) system.
Combining ECG and digital stethoscope technology into a compact handheld device offers insight into cardiac function. Clinicians will use DUO as a screening tool or prescribe it to outpatients to use at-home. The device wirelessly pairs with EKO’s HIPAA compliant app on iPhones, iPads, Windows PC, or Android devices enabling remote monitoring and diagnosis by a clinician or specialist.
In other developments in the heart monitoring space, CardioComm Solutions Inc., www.cardiocomm,com has been awarded a $567,079 grant from the Canada-Israel Industrial Research and Development Foundation (CIIRDF) www.ciirdf.ca to use the funds to perform R&D collaborative efforts with Health Watch Technologies Ltd., of Israel.
CIIRDF supports bilateral R&D initiatives by contributing up to 50 percent of joint project costs to a maximum of $800,000. The Foundation-enabled technologies have generated several hundreds of millions of dollars in economic value for Canadian and Israeli companies over the past decade alone.
Specifically, the funding will support the joint development of a novel wireless call center-based ECG and enable the use of the Health Watch http://healthwatch.cc wireless ECG to monitor vital signs by using a smart shirt complete with CardioComm’s GEMS™ arrhythmia management software.
CardioComm will develop the software and communications compatibility between Health Watch’s smart shirt and CardioComm’s ECG management Software as a Medical Device (SaMD) ECG software platform.
The companies are planning to integrate the smart shirt system with CardioComm’s GEM WIN and their next generation GEMS FLEX ECG solution. GEMS FLEX is a web-based application that can run on premises or in a cloud hosted environment. The system will also operate on all modern browsers and will be compatible for use on mobile devices.
CardioComm predicts that the integrated project will be completed by the end of the year so the first version of a web-based wireless 12 lead and wearable monitoring solution will be for sale by the end of 2017.